Small Nucleic Acid Drugs

Small nucleic acid drugs are the RNA-layer therapeutic modality discussed in 156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开. [[XiaoPTeacher|小P老师]] explains the route by moving from DNA transcription to RNA translation: instead of only inhibiting a protein after it is made, a small nucleic acid drug can reduce or silence RNA upstream.

The source highlights sequence specificity and delivery constraints. Because the intervention is sequence-based, target and off-target risk can be evaluated through genomic information, but practical delivery still shapes disease choice. The episode says many current applications focus on liver-expressed targets and metabolic disease areas such as lipid metabolism.

Key Claims

• RNA-layer intervention can reduce protein production at the source rather than only blocking protein function.
• Sequence specificity is an advantage, but delivery remains a bottleneck.
• Liver delivery is comparatively advanced, which shapes the early commercial and BD focus.
• The source treats 2024-2025 small nucleic acid BD as active, but still subject to clinical and commercialization proof.

Connections

• Biotech BD Data Validation Phase - modality watch item.
• Clinical Development Capability - clinical evidence and indication selection.
• GLP-1 Agonists - adjacent metabolic-drug commercial context, though with a different modality.